BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE

Bausch Health reported Q3 2026 revenue of $2.94 billion, up 10% reported and 8% organically year over year; adjusted diluted EPS rose 53% to $1.77, and adjusted EBITDA attributable to Bausch Health increased 32% to $1.305 billion. The company said Bausch Health excluding Bausch + Lomb delivered its 14th consecutive quarter of year-over-year revenue and adjusted EBITDA growth, reduced net debt by more than $500 million during the quarter, and raised full-year revenue, adjusted EBITDA and adjusted operating cash-flow guidance for that business. The board also authorized a $50 million share repurchase program, primarily to offset anticipated management equity-award dilution in 2027.

Analysis

The equity story is a debt-conversion story, not simply an EPS beat: durable operating cash must translate into sustained principal reduction before leverage discounts meaningfully narrow. The reported cash balance rose sharply, but gross debt remains substantial; verify the quarter’s actual debt movements and cash-flow reconciliation rather than treating cash growth or adjusted cash flow as equivalent to deleveraging. Management’s $50m repurchase is primarily dilution-offsetting and is immaterial beside the balance-sheet task.

The main earnings-quality question is concentration. Salix/Xifaxan is a key growth engine, while the disclosed 2027 Medicare negotiated-price exposure creates a defined medium-term pressure point: current growth can support near-term estimates while also raising the earnings base at risk. Solta’s reported growth masks organic contraction, so acquisition-led performance there should not be extrapolated. Bausch + Lomb’s organic growth is constructive for BLCO, but it does not eliminate BHC’s leverage or parent-level separation and governance execution risk.

Near term, guidance increases and cash generation can support BHC sentiment; over 1–3 months, watch debt paydown, segment mix and confirmation of guidance in subsequent quarters. Over 6–18 months, Xifaxan pricing, separation terms and the allocation of debt/costs between BHC and BLCO matter more than adjusted EPS. The contrarian risk to a bullish read is that adjusted metrics exclude recurring categories and do not settle the central question: how much cash remains after interest, legal payments and other excluded costs. A material slowdown in Salix or failure to reduce debt would falsify the deleveraging thesis.

Key Decisions for Investors

• Do not chase BHC at the open solely on the headline growth or buyback. Consider a staged long only after reviewing the call for debt repayment detail and confirming that operating cash converts to lower net debt; reassess if reported debt does not decline over the next quarter.
• For an existing BHC position, retain exposure only with an explicit catalyst/risk framework: monitor Salix organic growth and Xifaxan policy implementation, with a thesis break on a material Salix deceleration or guidance cut.
• Treat BLCO as a separate operating exposure: its organic growth supports a watchlist long, but require standalone profitability, cash flow and separation-allocation detail before sizing it as a clean relative-value hedge against BHC.
• Track GAAP-to-adjusted cash-flow reconciliation, legacy legal cash payments, interest burden, and the proposed Bausch + Lomb separation structure; these are higher-value catalysts than the dilution-offsetting repurchase.